{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:39:25Z","timestamp":1776040765177,"version":"3.50.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH052619"],"award-info":[{"award-number":["R01 MH052619"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH065702"],"award-info":[{"award-number":["R01MH065702"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DOD","award":["NF150083"],"award-info":[{"award-number":["NF150083"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA74177"],"award-info":[{"award-number":["R01 CA74177"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with a mutation in one copy of the neurofibromin gene (<jats:italic>NF1<\/jats:italic><jats:sup><jats:italic>+\/\u2212<\/jats:italic><\/jats:sup>). Even though approximately 40\u201360% of children with NF1 meet the criteria for attention deficit hyperactivity disorder (ADHD), very few preclinical studies, if any, have investigated alterations in impulsivity and risk-taking behavior. Mice with deletion of a single NF1 gene (<jats:italic>Nf1<\/jats:italic><jats:sup><jats:italic>+\/\u2212<\/jats:italic><\/jats:sup>) recapitulate many of the phenotypes of NF1 patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We compared wild-type (WT) and <jats:italic>Nf1<\/jats:italic><jats:sup><jats:italic>+\/\u2212<\/jats:italic><\/jats:sup> mouse strains to investigate differences in impulsivity and hyperactivity using the delay discounting task (DDT), cliff avoidance reaction (CAR) test, and open field. We also investigated whether treatment with the clinically effective alpha-2A adrenergic receptor agonist, guanfacine (0.3 mg\/kg, i.p.), would reverse deficits observed in behavioral inhibition.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p><jats:italic>Nf1<\/jats:italic><jats:sup><jats:italic>+\/\u2212<\/jats:italic><\/jats:sup> mice chose a higher percentage of smaller rewards when both 10- and 20-s delays were administered compared to WT mice, suggesting <jats:italic>Nf1<\/jats:italic><jats:sup><jats:italic>+\/\u2212<\/jats:italic><\/jats:sup> mice are more impulsive. When treated with guanfacine (0.3 mg\/kg, i.p.), <jats:italic>Nf1<\/jats:italic><jats:sup><jats:italic>+\/\u2212<\/jats:italic><\/jats:sup> mice exhibited decreased impulsive choice by waiting for the larger, delayed reward. <jats:italic>Nf1<\/jats:italic><jats:sup><jats:italic>+\/\u2212<\/jats:italic><\/jats:sup> mice also exhibited deficits in behavioral inhibition compared to WT mice in the CAR test by repetitively entering the outer edge of the platform where they risk falling. Treatment with guanfacine ameliorated these deficits. In addition, <jats:italic>Nf1<\/jats:italic><jats:sup><jats:italic>+\/\u2212<\/jats:italic><\/jats:sup> mice exhibited hyperactivity as increased distance was traveled compared to WT controls in the open field. This hyperactivity in <jats:italic>Nf1<\/jats:italic><jats:sup><jats:italic>+\/\u2212<\/jats:italic><\/jats:sup> mice was reduced with guanfacine pre-treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overall, our study confirms that <jats:italic>Nf1<\/jats:italic><jats:sup><jats:italic>+\/\u2212<\/jats:italic><\/jats:sup> mice exhibit deficits in behavioral inhibition in multiple contexts, a key feature of ADHD, and can be used as a model system to identify alterations in neural circuitry associated with symptoms of ADHD in children with NF1.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s11689-019-9304-y","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T08:02:33Z","timestamp":1579075353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-6834","authenticated-orcid":false,"given":"J. L.","family":"Lukkes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. P.","family":"Drozd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. D.","family":"Fitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. I.","family":"Molosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. W.","family":"Clapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"issue":"2","key":"9304_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11910-996-0036-5","volume":"6","author":"MT Acosta","year":"2006","unstructured":"Acosta MT, Gioia GA, Silva AJ. Neurofibromatosis type 1: new insights into neurocognitive issues. Curr Neurol Neurosci Rep. 2006;6(2):136\u201343.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"9304_CR2","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.ridd.2011.06.014","volume":"32","author":"Y Gilboa","year":"2011","unstructured":"Gilboa Y, Rosenblum S, Fattal-Valevski A, Toledano-Alhadef H, Rizzo AS, Josman N. Using a Virtual Classroom environment to describe the attention deficits profile of children with Neurofibromatosis type 1. Res Dev Disabil. 2011;32(6):2608\u201313.","journal-title":"Res Dev Disabil"},{"issue":"7","key":"9304_CR3","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1212\/01.wnl.0000179303.72345.ce","volume":"65","author":"SL Hyman","year":"2005","unstructured":"Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology. 2005;65(7):1037\u201344.","journal-title":"Neurology."},{"issue":"1","key":"9304_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/0883073812439435","volume":"28","author":"JC Isenberg","year":"2013","unstructured":"Isenberg JC, Templer A, Gao F, Titus JB, Gutmann DH. Attention skills in children with neurofibromatosis type 1. J Child Neurol. 2013;28(1):45\u20139.","journal-title":"J Child Neurol"},{"issue":"2","key":"9304_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1469-8749.2012.04399.x","volume":"55","author":"A Lehtonen","year":"2013","unstructured":"Lehtonen A, Howie E, Trump D, Huson SM. Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol. 2013;55(2):111\u201325.","journal-title":"Dev Med Child Neurol"},{"issue":"8","key":"9304_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/088307380201700811","volume":"17","author":"K North","year":"2002","unstructured":"North K, Hyman S, Barton B. Cognitive deficits in neurofibromatosis 1. J Child Neurol. 2002;17(8):605\u201312 discussion 627-609, 646-651.","journal-title":"J Child Neurol"},{"issue":"1","key":"9304_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<45::AID-AJMG9>3.0.CO;2-J","volume":"89","author":"S Ozonoff","year":"1999","unstructured":"Ozonoff S. Cognitive impairment in neurofibromatosis type 1. Am J Med Genet. 1999;89(1):45\u201352.","journal-title":"Am J Med Genet"},{"issue":"2","key":"9304_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11910-003-0064-3","volume":"3","author":"TL Rosser","year":"2003","unstructured":"Rosser TL, Packer RJ. Neurocognitive dysfunction in children with neurofibromatosis type 1. Curr Neurol Neurosci Rep. 2003;3(2):129\u201336.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"9304_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11910-996-0033-8","volume":"6","author":"RJ Packer","year":"2006","unstructured":"Packer RJ. Neurocognitive deficits in children with neurofibromatosis type 1. Curr Neurol Neurosci Rep. 2006;6(2):119\u201320.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"9304_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0092-8674(92)90407-4","volume":"69","author":"JE DeClue","year":"1992","unstructured":"DeClue JE, Papageorge AG, Fletcher JA, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 1992;69(2):265\u201373.","journal-title":"Cell."},{"issue":"4","key":"9304_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(90)90150-D","volume":"63","author":"GA Martin","year":"1990","unstructured":"Martin GA, Viskochil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990;63(4):843\u20139.","journal-title":"Cell."},{"issue":"6303","key":"9304_CR12","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/348678a0","volume":"348","author":"HR Bourne","year":"1990","unstructured":"Bourne HR, Wrischnik L, Kenyon C. Ras proteins. Some signal developments. Nature. 1990;348(6303):678\u20139.","journal-title":"Nature."},{"issue":"6305","key":"9304_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/349117a0","volume":"349","author":"HR Bourne","year":"1991","unstructured":"Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature. 1991;349(6305):117\u201327.","journal-title":"Nature."},{"issue":"6","key":"9304_CR14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/0092-8674(90)90054-I","volume":"61","author":"A Hall","year":"1990","unstructured":"Hall A. ras and GAP\u2014who\u2019s controlling whom? Cell. 1990;61(6):921\u20133.","journal-title":"Cell."},{"issue":"4","key":"9304_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0092-8674(90)90149-9","volume":"63","author":"GF Xu","year":"1990","unstructured":"Xu GF, Lin B, Tanaka K, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 1990;63(4):835\u201341.","journal-title":"Cell."},{"issue":"8","key":"9304_CR16","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1073\/pnas.88.8.3314","volume":"88","author":"T Satoh","year":"1991","unstructured":"Satoh T, Nakafuku M, Miyajima A, Kaziro Y. Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte\/macrophage colony-stimulating factor, but not from interleukin 4. Proc Natl Acad Sci U S A. 1991;88(8):3314\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"9304_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/dmcn.12043","volume":"55","author":"S Garg","year":"2013","unstructured":"Garg S, Lehtonen A, Huson SM, et al. Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. Dev Med Child Neurol. 2013;55(2):139\u201345.","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"9304_CR18","doi-asserted-by":"publisher","first-page":"e1642","DOI":"10.1542\/peds.2013-1868","volume":"132","author":"S Garg","year":"2013","unstructured":"Garg S, Green J, Leadbitter K, et al. Neurofibromatosis type 1 and autism spectrum disorder. Pediatrics. 2013;132(6):e1642\u20138.","journal-title":"Pediatrics."},{"issue":"3","key":"9304_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10519-010-9430-5","volume":"41","author":"SC Huijbregts","year":"2011","unstructured":"Huijbregts SC, de Sonneville LM. Does cognitive impairment explain behavioral and social problems of children with neurofibromatosis type 1? Behav Genet. 2011;41(3):430\u20136.","journal-title":"Behav Genet"},{"issue":"11","key":"9304_CR20","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/nn.3822","volume":"17","author":"AI Molosh","year":"2014","unstructured":"Molosh AI, Johnson PL, Spence JP, et al. Social learning and amygdala disruptions in Nf1 mice are rescued by blocking p21-activated kinase. Nat Neurosci. 2014;17(11):1583\u201390.","journal-title":"Nat Neurosci"},{"issue":"1","key":"9304_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.spen.2006.01.006","volume":"13","author":"TM Levine","year":"2006","unstructured":"Levine TM, Materek A, Abel J, O'Donnell M, Cutting LE. Cognitive profile of neurofibromatosis type 1. Semin Pediatr Neurol. 2006;13(1):8\u201320.","journal-title":"Semin Pediatr Neurol"},{"key":"9304_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.pbr.2018.09.014","volume":"241","author":"AI Molosh","year":"2018","unstructured":"Molosh AI, Shekhar A. Neurofibromatosis type 1 as a model system to study molecular mechanisms of autism spectrum disorder symptoms. Prog Brain Res. 2018;241:37\u201362.","journal-title":"Prog Brain Res"},{"issue":"3","key":"9304_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11065-018-9380-x","volume":"28","author":"AK Chisholm","year":"2018","unstructured":"Chisholm AK, Anderson VA, Pride NA, Malarbi S, North KN, Payne JM. Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis. Neuropsychol Rev. 2018;28(3):317\u201340.","journal-title":"Neuropsychol Rev"},{"issue":"12","key":"9304_CR24","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamapsychiatry.2016.2600","volume":"73","author":"SM Morris","year":"2016","unstructured":"Morris SM, Acosta MT, Garg S, et al. Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT). JAMA Psychiatry. 2016;73(12):1276\u201384.","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"9304_CR25","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s10803-014-2321-5","volume":"45","author":"S Garg","year":"2015","unstructured":"Garg S, Plasschaert E, Descheemaeker MJ, et al. Autism spectrum disorder profile in neurofibromatosis type I. J Autism Dev Disord. 2015;45(6):1649\u201357.","journal-title":"J Autism Dev Disord"},{"key":"9304_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1192\/bjp.bp.106.034389","volume":"190","author":"J Fayyad","year":"2007","unstructured":"Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402\u20139.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"9304_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/0278-2626(92)90064-S","volume":"20","author":"KL Shue","year":"1992","unstructured":"Shue KL, Douglas VI. Attention deficit hyperactivity disorder and the frontal lobe syndrome. Brain Cogn. 1992;20(1):104\u201324.","journal-title":"Brain Cogn"},{"issue":"3","key":"9304_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1076\/chin.6.3.185.3155","volume":"6","author":"CW Koth","year":"2000","unstructured":"Koth CW, Cutting LE, Denckla MB. The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol. 2000;6(3):185\u201394.","journal-title":"Child Neuropsychol"},{"key":"9304_CR29","doi-asserted-by":"crossref","unstructured":"Lion-Francois L, Herbillon V, Peyric E, et al. Attention and Executive Disorders in Neurofibromatosis 1: Comparison Between NF1 With ADHD Symptomatology (NF1 + ADHD) and ADHD Per Se. J Atten Disord. 2017;1087054717707579.","DOI":"10.1177\/1087054717707579"},{"issue":"1-2","key":"9304_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0022-510X(96)00022-6","volume":"138","author":"RE Ferner","year":"1996","unstructured":"Ferner RE, Hughes RA, Weinman J. Intellectual impairment in neurofibromatosis 1. J Neurol Sci. 1996;138(1-2):125\u201333.","journal-title":"J Neurol Sci"},{"issue":"6","key":"9304_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/87565641.2010.508670","volume":"35","author":"S Huijbregts","year":"2010","unstructured":"Huijbregts S, Swaab H, de Sonneville L. Cognitive and motor control in neurofibromatosis type I: influence of maturation and hyperactivity-inattention. Dev Neuropsychol. 2010;35(6):737\u201351.","journal-title":"Dev Neuropsychol"},{"issue":"1","key":"9304_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1037\/a0013927","volume":"23","author":"I Rowbotham","year":"2009","unstructured":"Rowbotham I, Pit-ten Cate IM, Sonuga-Barke EJ, Huijbregts SC. Cognitive control in adolescents with neurofibromatosis type 1. Neuropsychology. 2009;23(1):50\u201360.","journal-title":"Neuropsychology."},{"issue":"10","key":"9304_CR33","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.1469-8749.2012.04377.x","volume":"54","author":"K Lidzba","year":"2012","unstructured":"Lidzba K, Granstrom S, Lindenau J, Mautner VF. The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1. Dev Med Child Neurol. 2012;54(10):892\u20137.","journal-title":"Dev Med Child Neurol"},{"issue":"10","key":"9304_CR34","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1469-8749.2012.04357.x","volume":"54","author":"JM Payne","year":"2012","unstructured":"Payne JM, Arnold SS, Pride NA, North KN. Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1? Dev Med Child Neurol. 2012;54(10):898\u2013904.","journal-title":"Dev Med Child Neurol"},{"key":"9304_CR35","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.cortex.2014.10.019","volume":"64","author":"MJ Ribeiro","year":"2015","unstructured":"Ribeiro MJ, Violante IR, Bernardino I, Edden RA, Castelo-Branco M. Abnormal relationship between GABA, neurophysiology and impulsive behavior in neurofibromatosis type 1. Cortex. 2015;64:194\u2013208.","journal-title":"Cortex."},{"issue":"2","key":"9304_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/21622965.2012.704185","volume":"3","author":"A Roy","year":"2014","unstructured":"Roy A, Barbarot S, Roulin JL, et al. Is executive function specifically impaired in children with neurofibromatosis type 1? A neuropsychological investigation of cognitive flexibility. Appl Neuropsychol Child. 2014;3(2):94\u2013102.","journal-title":"Appl Neuropsychol Child"},{"issue":"4","key":"9304_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.tins.2012.12.002","volume":"36","author":"KA Diggs-Andrews","year":"2013","unstructured":"Diggs-Andrews KA, Gutmann DH. Modeling cognitive dysfunction in neurofibromatosis-1. Trends Neurosci. 2013;36(4):237\u201347.","journal-title":"Trends Neurosci"},{"issue":"22","key":"9304_CR38","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1093\/hmg\/ddq382","volume":"19","author":"JA Brown","year":"2010","unstructured":"Brown JA, Emnett RJ, White CR, et al. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Hum Mol Genet. 2010;19(22):4515\u201328.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"9304_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0006-3223(95)00101-8","volume":"39","author":"FX Castellanos","year":"1996","unstructured":"Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry. 1996;39(1):33\u201341.","journal-title":"Biol Psychiatry"},{"issue":"21","key":"9304_CR40","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.cub.2005.09.043","volume":"15","author":"W Li","year":"2005","unstructured":"Li W, Cui Y, Kushner SA, et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol. 2005;15(21):1961\u20137.","journal-title":"Curr Biol"},{"issue":"11","key":"9304_CR41","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/mp.2015.48","volume":"20","author":"A Omrani","year":"2015","unstructured":"Omrani A, van der Vaart T, Mientjes E, et al. HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. Mol Psychiatry. 2015;20(11):1311\u201321.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"9304_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00213-011-2408-z","volume":"219","author":"AB Fernando","year":"2012","unstructured":"Fernando AB, Economidou D, Theobald DE, et al. Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists. Psychopharmacology. 2012;219(2):341\u201352.","journal-title":"Psychopharmacology"},{"key":"9304_CR43","doi-asserted-by":"crossref","unstructured":"Freund N, Jordan CJ, Lukkes JL, Norman KJ, Andersen SL. Juvenile exposure to methylphenidate and guanfacine in rats: effects on early delay discounting and later cocaine-taking behavior. Psychopharmacology. 2018.","DOI":"10.1007\/s00213-018-5096-0"},{"issue":"19","key":"9304_CR44","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1007\/s00213-015-4001-3","volume":"232","author":"YS Mineur","year":"2015","unstructured":"Mineur YS, Bentham MP, Zhou WL, Plantenga ME, McKee SA, Picciotto MR. Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice. Psychopharmacology. 2015;232(19):3539\u201349.","journal-title":"Psychopharmacology"},{"issue":"20","key":"9304_CR45","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1111\/bph.12860","volume":"171","author":"K Pillidge","year":"2014","unstructured":"Pillidge K, Porter AJ, Dudley JA, Tsai YC, Heal DJ, Stanford SC. The behavioural response of mice lacking NK(1) receptors to guanfacine resembles its clinical profile in treatment of ADHD. Br J Pharmacol. 2014;171(20):4785\u201396.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"9304_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27\u201331.","journal-title":"J Basic Clin Pharm"},{"issue":"4","key":"9304_CR47","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00213-013-3009-9","volume":"227","author":"M Yamashita","year":"2013","unstructured":"Yamashita M, Sakakibara Y, Hall FS, et al. Impaired cliff avoidance reaction in dopamine transporter knockout mice. Psychopharmacology. 2013;227(4):741\u20139.","journal-title":"Psychopharmacology"},{"issue":"3","key":"9304_CR48","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0014-2999(89)90346-4","volume":"166","author":"M Hiramatsu","year":"1989","unstructured":"Hiramatsu M, Cho AK, Nabeshima T. Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol. 1989;166(3):359\u201366.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"9304_CR49","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/0006-8993(73)90302-8","volume":"55","author":"I Creese","year":"1973","unstructured":"Creese I, Iversen SD. Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res. 1973;55(2):369\u201382.","journal-title":"Brain Res"},{"key":"9304_CR50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.bbr.2014.05.024","volume":"270","author":"N Freund","year":"2014","unstructured":"Freund N, MacGillivilray HT, Thompson BS, et al. Sex-dependent changes in ADHD-like behaviors in juvenile rats following cortical dopamine depletion. Behav Brain Res. 2014;270:357\u201363.","journal-title":"Behav Brain Res"},{"issue":"2","key":"9304_CR51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00213-005-0215-0","volume":"184","author":"MC Olmstead","year":"2006","unstructured":"Olmstead MC, Hellemans KG, Paine TA. Alcohol-induced impulsivity in rats: an effect of cue salience? Psychopharmacology. 2006;184(2):221\u20138.","journal-title":"Psychopharmacology"},{"issue":"8","key":"9304_CR52","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00213-013-3399-8","volume":"231","author":"KC Sonntag","year":"2014","unstructured":"Sonntag KC, Brenhouse HC, Freund N, Thompson BS, Puhl M, Andersen SL. Viral over-expression of D1 dopamine receptors in the prefrontal cortex increase high-risk behaviors in adults: comparison with adolescents. Psychopharmacology. 2014;231(8):1615\u201326.","journal-title":"Psychopharmacology"},{"issue":"3","key":"9304_CR53","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1017\/S0012162201001876","volume":"44","author":"VF Mautner","year":"2002","unstructured":"Mautner VF, Kluwe L, Thakker SD, Leark RA. Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol. 2002;44(3):164\u201370.","journal-title":"Dev Med Child Neurol"},{"key":"9304_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cortex.2017.04.022","volume":"93","author":"NA Pride","year":"2017","unstructured":"Pride NA, Korgaonkar MS, North KN, Barton B, Payne JM. The neural basis of deficient response inhibition in children with neurofibromatosis type 1: Evidence from a functional MRI study. Cortex. 2017;93:1\u201311.","journal-title":"Cortex."},{"issue":"7","key":"9304_CR55","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1080\/87565641.2012.695831","volume":"37","author":"NA Pride","year":"2012","unstructured":"Pride NA, Payne JM, North KN. The impact of ADHD on the cognitive and academic functioning of children with NF1. Dev Neuropsychol. 2012;37(7):590\u2013600.","journal-title":"Dev Neuropsychol"},{"issue":"5","key":"9304_CR56","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s10519-005-9040-9","volume":"36","author":"FX Coude","year":"2006","unstructured":"Coude FX, Mignot C, Lyonnet S, Munnich A. Academic impairment is the most frequent complication of neurofibromatosis type-1 (NF1) in children. Behav Genet. 2006;36(5):660\u20134.","journal-title":"Behav Genet"},{"issue":"3","key":"9304_CR57","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jpeds.2008.08.045","volume":"154","author":"LC Krab","year":"2009","unstructured":"Krab LC, Oostenbrink R, de Goede-Bolder A, Aarsen FK, Elgersma Y, Moll HA. Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior. J Pediatr. 2009;154(3):420\u20135 425 e421.","journal-title":"J Pediatr"},{"issue":"9","key":"9304_CR58","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.euroneuro.2014.06.016","volume":"24","author":"KP Schulz","year":"2014","unstructured":"Schulz KP, Clerkin SM, Newcorn JH, Halperin JM, Fan J. Guanfacine modulates the emotional biasing of amygdala-prefrontal connectivity for cognitive control. Eur Neuropsychopharmacol. 2014;24(9):1444\u201353.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"9304_CR59","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jaac.2015.08.016","volume":"54","author":"TE Wilens","year":"2015","unstructured":"Wilens TE, Robertson B, Sikirica V, et al. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit\/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(11):916\u201325 e912.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"9304_CR60","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/j.1469-8749.2010.03639.x","volume":"52","author":"S Huijbregts","year":"2010","unstructured":"Huijbregts S, Jahja R, De Sonneville L, de Breij S, Swaab-Barneveld H. Social information processing in children and adolescents with neurofibromatosis type 1. Dev Med Child Neurol. 2010;52(7):620\u20135.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"9304_CR61","first-page":"45","volume":"85","author":"AF Arnsten","year":"2012","unstructured":"Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012;85(1):45\u201358.","journal-title":"Yale J Biol Med"},{"issue":"2","key":"9304_CR62","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.pbb.2011.01.020","volume":"99","author":"AF Arnsten","year":"2011","unstructured":"Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit\/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99(2):211\u20136.","journal-title":"Pharmacol Biochem Behav"},{"issue":"5","key":"9304_CR63","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1023\/A:1025405216339","volume":"31","author":"JN Epstein","year":"2003","unstructured":"Epstein JN, Erkanli A, Conners CK, Klaric J, Costello JE, Angold A. Relations between Continuous Performance Test performance measures and ADHD behaviors. J Abnorm Child Psychol. 2003;31(5):543\u201354.","journal-title":"J Abnorm Child Psychol"},{"issue":"1","key":"9304_CR64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4062\/biomolther.2012.20.1.125","volume":"20","author":"P Kim","year":"2012","unstructured":"Kim P, Choi I, Pena IC, et al. A simple behavioral paradigm to measure impulsive behavior in an animal model of attention deficit hyperactivity disorder (ADHD) of the spontaneously hypertensive rats. Biomol Ther (Seoul). 2012;20(1):125\u201331.","journal-title":"Biomol Ther (Seoul)"},{"issue":"1","key":"9304_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1866-1955-5-3","volume":"5","author":"IR Violante","year":"2013","unstructured":"Violante IR, Ribeiro MJ, Silva ED, Castelo-Branco M. Gyrification, cortical and subcortical morphometry in neurofibromatosis type 1: an uneven profile of developmental abnormalities. J Neurodev Disord. 2013;5(1):3.","journal-title":"J Neurodev Disord"},{"key":"9304_CR66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13229-017-0166-4","volume":"8","author":"J Goncalves","year":"2017","unstructured":"Goncalves J, Violante IR, Sereno J, et al. Testing the excitation\/inhibition imbalance hypothesis in a mouse model of the autism spectrum disorder: in vivo neurospectroscopy and molecular evidence for regional phenotypes. Mol Autism. 2017;8:47.","journal-title":"Mol Autism"},{"issue":"29","key":"9304_CR67","doi-asserted-by":"publisher","first-page":"13141","DOI":"10.1073\/pnas.1004829107","volume":"107","author":"C Shilyansky","year":"2010","unstructured":"Shilyansky C, Karlsgodt KH, Cummings DM, et al. Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proc Natl Acad Sci U S A. 2010;107(29):13141\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6871","key":"9304_CR68","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nature711","volume":"415","author":"RM Costa","year":"2002","unstructured":"Costa RM, Federov NB, Kogan JH, et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature. 2002;415(6871):526\u201330.","journal-title":"Nature."},{"issue":"3","key":"9304_CR69","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2008.09.060","volume":"135","author":"Y Cui","year":"2008","unstructured":"Cui Y, Costa RM, Murphy GG, et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell. 2008;135(3):549\u201360.","journal-title":"Cell."},{"key":"9304_CR70","doi-asserted-by":"publisher","first-page":"107547","DOI":"10.1016\/j.neuropharm.2019.02.029","volume":"156","author":"M Okada","year":"2019","unstructured":"Okada M, Fukuyama K, Kawano Y, Shiroyama T, Suzuki D, Ueda Y. Effects of acute and sub-chronic administrations of guanfacine on catecholaminergic transmissions in the orbitofrontal cortex. Neuropharmacology. 2019;156:107547.","journal-title":"Neuropharmacology"},{"issue":"2","key":"9304_CR71","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1060028013510699","volume":"48","author":"A Sharma","year":"2014","unstructured":"Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48(2):209\u201325.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"9304_CR72","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/0306-4522(96)00202-3","volume":"74","author":"A Gasbarri","year":"1996","unstructured":"Gasbarri A, Sulli A, Innocenzi R, Pacitti C, Brioni JD. Spatial memory impairment induced by lesion of the mesohippocampal dopaminergic system in the rat. Neuroscience. 1996;74(4):1037\u201344.","journal-title":"Neuroscience."},{"issue":"2","key":"9304_CR73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0014-2999(99)00573-7","volume":"383","author":"M El-Ghundi","year":"1999","unstructured":"El-Ghundi M, Fletcher PJ, Drago J, Sibley DR, O'Dowd BF, George SR. Spatial learning deficit in dopamine D(1) receptor knockout mice. Eur J Pharmacol. 1999;383(2):95\u2013106.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"9304_CR74","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.pnpbp.2010.05.017","volume":"34","author":"M Xu","year":"2010","unstructured":"Xu M, Xing Q, Li S, et al. Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2010;34(6):1026\u201332.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"9304_CR75","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ana.23793","volume":"73","author":"KA Diggs-Andrews","year":"2013","unstructured":"Diggs-Andrews KA, Tokuda K, Izumi Y, Zorumski CF, Wozniak DF, Gutmann DH. Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. Ann Neurol. 2013;73(2):309\u201315.","journal-title":"Ann Neurol"},{"issue":"2","key":"9304_CR76","doi-asserted-by":"publisher","first-page":"RC121","DOI":"10.1523\/JNEUROSCI.21-02-j0001.2001","volume":"21","author":"ND Volkow","year":"2001","unstructured":"Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121.","journal-title":"J Neurosci"},{"issue":"3","key":"9304_CR77","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1176\/appi.ajp.163.3.387","volume":"163","author":"TJ Spencer","year":"2006","unstructured":"Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry. 2006;163(3):387\u201395.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"9304_CR78","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.expneurol.2011.09.005","volume":"232","author":"JA Brown","year":"2011","unstructured":"Brown JA, Xu J, Diggs-Andrews KA, Wozniak DF, Mach RH, Gutmann DH. PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Exp Neurol. 2011;232(2):333\u20138.","journal-title":"Exp Neurol"},{"issue":"10","key":"9304_CR79","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1586\/ern.10.133","volume":"10","author":"AF Arnsten","year":"2010","unstructured":"Arnsten AF. The use of \u03b1-2A adrenergic agonists for the treatment of attention-deficit\/hyperactivity disorder. Expert Rev Neurother. 2010;10(10):1595\u2013605.","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"9304_CR80","first-page":"107","volume":"44","author":"C Alamo","year":"2016","unstructured":"Alamo C, Lopez-Munoz F, Sanchez-Garcia J. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd). Actas Esp Psiquiatr. 2016;44(3):107\u201312.","journal-title":"Actas Esp Psiquiatr"},{"issue":"12","key":"9304_CR81","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.biopsych.2011.01.027","volume":"69","author":"AF Arnsten","year":"2011","unstructured":"Arnsten AF. Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry. 2011;69(12):e89\u201399.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"9304_CR82","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.pharmthera.2006.11.006","volume":"113","author":"BP Ramos","year":"2007","unstructured":"Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther. 2007;113(3):523\u201336.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"9304_CR83","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10519-010-9437-y","volume":"41","author":"LC Bidwell","year":"2011","unstructured":"Bidwell LC, Willcutt EG, McQueen MB, et al. A family based association study of DRD4, DAT1, and 5HTT and continuous traits of attention-deficit hyperactivity disorder. Behav Genet. 2011;41(1):165\u201374.","journal-title":"Behav Genet"},{"issue":"2","key":"9304_CR84","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2007.03.015","volume":"129","author":"M Wang","year":"2007","unstructured":"Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129(2):397\u2013410.","journal-title":"Cell."},{"issue":"3","key":"9304_CR85","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0893-133X(00)00111-1","volume":"23","author":"RA Avery","year":"2000","unstructured":"Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AF. The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology. 2000;23(3):240\u20139.","journal-title":"Neuropsychopharmacology."}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-019-9304-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s11689-019-9304-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-019-9304-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:06:00Z","timestamp":1610582760000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneurodevdisorders.biomedcentral.com\/articles\/10.1186\/s11689-019-9304-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9304"],"URL":"https:\/\/doi.org\/10.1186\/s11689-019-9304-y","relation":{},"ISSN":["1866-1947","1866-1955"],"issn-type":[{"value":"1866-1947","type":"print"},{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"20 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal care procedures were conducted in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals (NIH Publication No. 80-23) revised 1996. All procedures were approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee (Protocol No. 11082).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}